Ariella Hanker

Citée par

	Toutes	Depuis 2019
Citations	2513	2095
indice h	19	18
indice i10	27	24

540

270

135

405

20102011201220132014201520162017201820192020202120222023202410 10 9 10 32 32 84 85 131 148 274 421 467 540 234

Accès public

Tout afficher

27 articles

1 article

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

Dhivya R. SudhanInstructor, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical CenterAdresse e-mail validée de utsouthwestern.edu
Kyung-min LeeHanyang UniversityAdresse e-mail validée de hanyang.ac.kr
Alberto ServettoUniversity of Naples Federico II, Naples, ItalyAdresse e-mail validée de unina.it
Alshad S. LalaniVP - Translational Sciences, Zymeworks Inc.Adresse e-mail validée de zymeworks.com
Jens MeilerVanderbilt University & University LeipzigAdresse e-mail validée de meilerlab.org
Rebecca S. CookAssociate Professor of Biomedical Engineering, Vanderbilt UniversityAdresse e-mail validée de vanderbilt.edu
Sumanta Chatterjee, PhDInstructor, Genetic Drug Engineering Program, Biomedical Engineering, UT Southwestern Medical CenterAdresse e-mail validée de utsouthwestern.edu
Angel Guerrero-ZotanoInstituto Valenciano de OncologiaAdresse e-mail validée de fivo.org
Jonathan H. SheehanAssociate Professor, Washington Univ. School of Medicine in St. LouisAdresse e-mail validée de wustl.edu
Saurabh MendirattaUT southwestern Medical CenterAdresse e-mail validée de utsouthwestern.edu
Justin M. BalkoProfessor of Medicine, and Pathology, Microbiology, and Immunology, Vanderbilt UniversityAdresse e-mail validée de vumc.org
Gregory SliwoskiVanderbilt UniversityAdresse e-mail validée de vanderbilt.edu
Reto FiolkaAssistant Professor, Departments of Cell Biology and Bioinformatics, UTSW, DallasAdresse e-mail validée de UTsouthwestern.edu
David M HymanLoxo Oncology, Eli LillyAdresse e-mail validée de loxooncology.com
Zhongming ZhaoUniversity of Texas Health Science Center at HoustonAdresse e-mail validée de uth.tmc.edu
Feixiong ChengCleveland ClinicAdresse e-mail validée de ccf.org
Ralf KittlerAssociate Professor of Pharmacology, UT Southwestern Medical CenterAdresse e-mail validée de utsouthwestern.edu
Luigi FormisanoUniversity of Naples Federico IIAdresse e-mail validée de unina.it
David SolitDirector, Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterAdresse e-mail validée de mskcc.org
Adam D. PfefferleUNC Chapel HillAdresse e-mail validée de email.unc.edu

Suivre

Ariella Hanker

UT Southwestern Medical Center

Adresse e-mail validée de UTsouthwestern.edu - Page d'accueil

cancer research translational medicine targeted therapy


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
Overcoming endocrine resistance in breast cancer AB Hanker, DR Sudhan, CL Arteaga Cancer cell 37 (4), 496-513, 2020	535	2020
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer L Formisano, Y Lu, A Servetto, AB Hanker, VM Jansen, JA Bauer, ... Nature communications 10 (1), 1373, 2019	306	2019
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies AB Hanker, AD Pfefferle, JM Balko, MG Kuba, CD Young, V Sánchez, ... Proceedings of the National Academy of Sciences 110 (35), 14372-14377, 2013	197	2013
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer M Janiszewska, L Liu, V Almendro, Y Kuang, C Paweletz, RA Sakr, ... Nature genetics 47 (10), 1212-1219, 2015	181	2015
Challenges for the clinical development of PI3K inhibitors: strategies to improve their impact in solid tumors AB Hanker, V Kaklamani, CL Arteaga Cancer discovery 9 (4), 482-491, 2019	165*	2019
A versatile oblique plane microscope for large-scale and high-resolution imaging of subcellular dynamics E Sapoznik, BJ Chang, J Huh, RJ Ju, EV Azarova, T Pohlkamp, ES Welf, ... Elife 9, e57681, 2020	139	2020
Genomic alterations of ERBB receptors in cancer: clinical implications R Mishra, AB Hanker, JT Garrett Oncotarget 8 (69), 114371, 2017	119	2017
Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling AB Hanker, N Mitin, RS Wilder, EP Henske, F Tamanoi, AD Cox, CJ Der Oncogene 29 (3), 380-391, 2010	111	2010
An Acquired HER2 ^T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer AB Hanker, MR Brewer, JH Sheehan, JP Koch, GR Sliwoski, R Nagy, ... Cancer discovery 7 (6), 575-585, 2017	100*	2017
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2⁺ Breast Cancer AB Hanker, MV Estrada, G Bianchini, PD Moore, J Zhao, F Cheng, ... Cancer research 77 (12), 3280-3292, 2017	92	2017
HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2 AB Hanker, JT Garrett, MV Estrada, PD Moore, PG Ericsson, JP Koch, ... Clinical Cancer Research 23 (15), 4323-4334, 2017	81	2017
Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results AG Sorace, CC Quarles, JG Whisenant, AB Hanker, JO McIntyre, ... Breast cancer research and treatment 155, 273-284, 2016	51	2016
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity AB Hanker, BP Brown, J Meiler, A Marín, HS Jayanthan, D Ye, CC Lin, ... Cancer cell 39 (8), 1099-1114. e8, 2021	50	2021
Hyperactivation of TORC1 drives resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers DR Sudhan, A Guerrero-Zotano, H Won, PG Ericsson, A Servetto, ... Cancer cell 37 (2), 183-199. e5, 2020	47	2020
Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness PK Parida, M Marquez-Palencia, V Nair, AK Kaushik, K Kim, J Sudderth, ... Cell metabolism 34 (1), 90-105. e7, 2022	41	2022
Activating PIK3CA mutations induce an epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase (ERK) paracrine signaling axis in basal-like breast cancer CD Young, LJ Zimmerman, D Hoshino, L Formisano, AB Hanker, ... Molecular & cellular proteomics 14 (7), 1959-1976, 2015	39	2015
Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER⁺ Breast Cancer A Servetto, R Kollipara, L Formisano, CC Lin, KM Lee, DR Sudhan, ... Clinical Cancer Research 27 (15), 4379-4396, 2021	38	2021
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer K Lee, AL Guerrero-Zotano, A Servetto, DR Sudhan, CC Lin, L Formisano, ... Nature communications 11 (1), 5488, 2020	37	2020
gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer L Formisano, Y Lu, VM Jansen, JA Bauer, AB Hanker, ME Sanders, ... Cancer Research 77 (13_Supplement), 1008-1008, 2017	24*	2017
Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer K Lee, CC Lin, A Servetto, J Bae, V Kandagatla, D Ye, GM Kim, ... Cancer immunology research 10 (7), 829-843, 2022	16	2022

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–20

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs